Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.

Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P.

Proc Natl Acad Sci U S A. 2019 Jul 3. pii: 201821409. doi: 10.1073/pnas.1821409116. [Epub ahead of print]

2.

Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson's disease.

Waldthaler J, Tsitsi P, Svenningsson P.

NPJ Parkinsons Dis. 2019 Jun 24;5:11. doi: 10.1038/s41531-019-0083-7. eCollection 2019.

3.

Editorial: Update on movement disorders.

Svenningsson P, Frucht SJ.

Curr Opin Neurol. 2019 Aug;32(4):564-565. doi: 10.1097/WCO.0000000000000709. No abstract available.

PMID:
31246704
4.

Update on movement disorders.

Svenningsson P, Frucht SJ.

Curr Opin Neurol. 2019 Jun 18. doi: 10.1097/WCO.0000000000000709. [Epub ahead of print] No abstract available.

PMID:
31219826
5.

Involuntary movements, vocalizations and cognitive decline.

Sveinsson O, Udd B, Svenningsson P, Gassner C, Engström C, Laffita-Mesa J, Solders G, Hertegård S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M.

Parkinsonism Relat Disord. 2019 May 29. pii: S1353-8020(19)30250-0. doi: 10.1016/j.parkreldis.2019.05.029. [Epub ahead of print] No abstract available.

PMID:
31153763
6.

MCEE Mutations in an Adult Patient with Parkinson's Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid.

Andréasson M, Zetterström RH, von Döbeln U, Wedell A, Svenningsson P.

Int J Mol Sci. 2019 May 29;20(11). pii: E2631. doi: 10.3390/ijms20112631.

7.

Corticobasal degeneration: advances in clinicopathology and biomarkers.

Svenningsson P.

Curr Opin Neurol. 2019 Aug;32(4):597-603. doi: 10.1097/WCO.0000000000000707.

PMID:
31145128
8.

GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-β-epoxide increases levels of total α-synuclein in SH-SY5Y cells.

Zurbruegg M, Chan MY, Svenningsson P.

Neurosci Lett. 2019 Jul 27;706:217-222. doi: 10.1016/j.neulet.2019.05.027. Epub 2019 May 15.

PMID:
31102708
9.

Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition.

Vallianatou T, Shariatgorji M, Nilsson A, Fridjonsdottir E, Källback P, Schintu N, Svenningsson P, Andrén PE.

Neuropsychopharmacology. 2019 Apr 22. doi: 10.1038/s41386-019-0397-5. [Epub ahead of print]

PMID:
31009936
10.

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.

Sjöström H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, Svenningsson P, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6079. doi: 10.1038/s41598-019-42565-4.

11.

Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes.

Reyes JF, Sackmann C, Hoffmann A, Svenningsson P, Winkler J, Ingelsson M, Hallbeck M.

Acta Neuropathol. 2019 Jul;138(1):23-47. doi: 10.1007/s00401-019-02007-x. Epub 2019 Apr 11.

12.

First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L.

Hertz E, Thörnqvist M, Holmberg B, Machaczka M, Sidransky E, Svenningsson P.

Mov Disord Clin Pract. 2019 Mar 7;6(3):254-258. doi: 10.1002/mdc3.12743. eCollection 2019 Mar.

PMID:
30949558
13.

SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal Neurodifferentiation.

Calvo-Garrido J, Maffezzini C, Schober FA, Clemente P, Uhlin E, Kele M, Stranneheim H, Lesko N, Bruhn H, Svenningsson P, Falk A, Wedell A, Freyer C, Wredenberg A.

Stem Cell Reports. 2019 Apr 9;12(4):696-711. doi: 10.1016/j.stemcr.2019.01.023. Epub 2019 Feb 28.

14.

Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease.

Vinding MC, Tsitsi P, Piitulainen H, Waldthaler J, Jousmäki V, Ingvar M, Svenningsson P, Lundqvist D.

Sci Rep. 2019 Feb 22;9(1):2604. doi: 10.1038/s41598-019-39204-3.

15.

Decreased Cerebrospinal Fluid Aβ42 in Patients with Idiopathic Parkinson's Disease and White Matter Lesions.

Markaki I, Klironomos S, Svenningsson P.

J Parkinsons Dis. 2019;9(2):361-367. doi: 10.3233/JPD-181486.

PMID:
30714972
16.

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Green H, Tsitsi P, Markaki I, Aarsland D, Svenningsson P.

CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x. Review.

17.

On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review).

Björkhem I, Leoni V, Svenningsson P.

J Steroid Biochem Mol Biol. 2019 Apr;188:86-89. doi: 10.1016/j.jsbmb.2018.12.009. Epub 2018 Dec 23. Review.

PMID:
30586624
18.

Variant ataxia-telangiectasia with prominent camptocormia.

Paucar M, Schechtmann G, Taylor AM, Svenningsson P.

Parkinsonism Relat Disord. 2019 May;62:253-255. doi: 10.1016/j.parkreldis.2018.12.017. Epub 2018 Dec 17. No abstract available.

PMID:
30579816
19.

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Svenningsson P, Johansson A, Nyholm D, Tsitsi P, Hansson F, Sonesson C, Tedroff J.

NPJ Parkinsons Dis. 2018 Dec 6;4:35. doi: 10.1038/s41531-018-0071-3. eCollection 2018.

20.

GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells.

Hertz E, Terenius L, Vukojević V, Svenningsson P.

Neuropharmacology. 2019 Jul 1;152:51-57. doi: 10.1016/j.neuropharm.2018.11.009. Epub 2018 Nov 10.

21.

WITHDRAWN: Novel Xp21.1 deletion associated with unusual features in a large McLeod syndrome kindred.

Sveinsson O, Udd B, Svenningsson P, Gassner C, Engström C, Laffita-Mesa JM, Solders G, Hertegård S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M.

Parkinsonism Relat Disord. 2018 Oct 8. pii: S1353-8020(18)30399-7. doi: 10.1016/j.parkreldis.2018.09.014. [Epub ahead of print] No abstract available.

PMID:
30305234
22.

Eye movements during reading in Parkinson's disease: A pilot study.

Waldthaler J, Tsitsi P, Seimyr GÖ, Benfatto MN, Svenningsson P.

Mov Disord. 2018 Oct;33(10):1661-1662. doi: 10.1002/mds.105. Epub 2018 Oct 8. No abstract available.

PMID:
30298615
23.

Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Fazio P, Paucar M, Svenningsson P, Varrone A.

Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y. Review.

24.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375. doi: 10.1007/s00259-018-4161-6. Epub 2018 Oct 1.

25.

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome.

Björkhem I, Patra K, Boxer AL, Svenningsson P.

Front Neurol. 2018 Sep 7;9:756. doi: 10.3389/fneur.2018.00756. eCollection 2018.

26.

Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool.

Lazarevic V, Yang Y, Ivanova D, Fejtova A, Svenningsson P.

Neuropharmacology. 2018 Dec;143:38-48. doi: 10.1016/j.neuropharm.2018.09.021. Epub 2018 Sep 14.

PMID:
30222983
27.

Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations.

Paucar M, Pajak A, Freyer C, Bergendal Å, Döry M, Laffita-Mesa JM, Stranneheim H, Lagerstedt-Robinson K, Savitcheva I, Walker RH, Wedell A, Wredenberg A, Svenningsson P.

Neurology. 2018 Oct 9;91(15):710-712. doi: 10.1212/WNL.0000000000006320. Epub 2018 Sep 14. No abstract available.

28.

Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy.

Paucar M, Nennesmo I, Svenningsson P.

Front Genet. 2018 Aug 15;9:317. doi: 10.3389/fgene.2018.00317. eCollection 2018.

29.

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Siebzehnrübl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen HP, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, Petersén Å, von Hörsten S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8765-E8774. doi: 10.1073/pnas.1807962115. Epub 2018 Aug 27.

30.

GLRA1 mutation and long-term follow-up of the first hyperekplexia family.

Paucar M, Waldthaler J, Svenningsson P.

Neurol Genet. 2018 Aug 7;4(4):e259. doi: 10.1212/NXG.0000000000000259. eCollection 2018 Aug. No abstract available.

31.

Dynamic lateral organization of opioid receptors (kappa, muwt and muN40D ) in the plasma membrane at the nanoscale level.

Rogacki MK, Golfetto O, Tobin SJ, Li T, Biswas S, Jorand R, Zhang H, Radoi V, Ming Y, Svenningsson P, Ganjali D, Wakefield DL, Sideris A, Small AR, Terenius L, Jovanović-Talisman T, Vukojević V.

Traffic. 2018 May 28. doi: 10.1111/tra.12582. [Epub ahead of print]

32.

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

Jaiteh M, Zeifman A, Saarinen M, Svenningsson P, Bréa J, Loza MI, Carlsson J.

J Med Chem. 2018 Jun 28;61(12):5269-5278. doi: 10.1021/acs.jmedchem.8b00204. Epub 2018 Jun 15.

PMID:
29792714
33.

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.

Zhang X, Mantas I, Alvarsson A, Yoshitake T, Shariatgorji M, Pereira M, Nilsson A, Kehr J, Andrén PE, Millan MJ, Chergui K, Svenningsson P.

Front Pharmacol. 2018 Mar 1;9:166. doi: 10.3389/fphar.2018.00166. eCollection 2018.

34.

Novel Features and Abnormal Pattern of Cerebral Glucose Metabolism in Spinocerebellar Ataxia 19.

Paucar M, Bergendal Å, Gustavsson P, Nordenskjöld M, Laffita-Mesa J, Savitcheva I, Svenningsson P.

Cerebellum. 2018 Aug;17(4):465-476. doi: 10.1007/s12311-018-0927-4.

35.

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A.

Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13.

PMID:
29436751
36.

A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability.

Vallianatou T, Strittmatter N, Nilsson A, Shariatgorji M, Hamm G, Pereira M, Källback P, Svenningsson P, Karlgren M, Goodwin RJA, Andrén PE.

Neuroimage. 2018 May 15;172:808-816. doi: 10.1016/j.neuroimage.2018.01.013. Epub 2018 Jan 10.

PMID:
29329980
37.

Paroxysmal Kinesigenic Dyskinesia.

Paucar M, Malmgren H, Svenningsson P.

Tremor Other Hyperkinet Mov (N Y). 2017 Dec 12;7:529. doi: 10.7916/D8R79N2F. eCollection 2017.

38.

Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.

Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K.

Mol Psychiatry. 2018 Oct;23(10):2066-2077. doi: 10.1038/mp.2017.239. Epub 2017 Nov 21.

PMID:
29158578
39.

Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia.

Riggare S, Unruh KT, Sturr J, Domingos J, Stamford JA, Svenningsson P, Hägglund M.

Methods Inf Med. 2017 Oct 24;56(99):e123-e128. doi: 10.3414/ME16-02-0040. Epub 2017 Oct 24.

40.

Quantitative susceptibility mapping differentiates between parkinsonian disorders.

Sjöström H, Granberg T, Westman E, Svenningsson P.

Parkinsonism Relat Disord. 2017 Nov;44:51-57. doi: 10.1016/j.parkreldis.2017.08.029. Epub 2017 Sep 1.

PMID:
28886909
41.

Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.

Andréasson M, Brodin L, Laffita-Mesa JM, Svenningsson P.

J Parkinsons Dis. 2017;7(4):619-628. doi: 10.3233/JPD-171127.

PMID:
28759974
42.

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.

Neurology. 2017 Aug 22;89(8):845-853. doi: 10.1212/WNL.0000000000004264. Epub 2017 Jul 28.

43.

Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher's Disease Type 3.

Blume J, Beniaminov S, Kämpe Björkvall C, Machaczka M, Svenningsson P.

Front Neurol. 2017 Jun 22;8:295. doi: 10.3389/fneur.2017.00295. eCollection 2017.

44.

Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder.

Svenningsson P, Pålhagen S, Mathé AA.

Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102. eCollection 2017.

45.

Synaptic proteins in CSF relate to Parkinson's disease stage markers.

Bereczki E, Bogstedt A, Höglund K, Tsitsi P, Brodin L, Ballard C, Svenningsson P, Aarsland D.

NPJ Parkinsons Dis. 2017 Feb 8;3:7. doi: 10.1038/s41531-017-0008-2. eCollection 2017.

46.

Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.

Leinartaité L, Svenningsson P.

Trends Pharmacol Sci. 2017 Aug;38(8):749-760. doi: 10.1016/j.tips.2017.05.006. Epub 2017 Jun 16. Review.

PMID:
28629580
47.

Patients with Parkinson's disease display a dopamine therapy related negative bias and an enlarged range in emotional responses to facial emotional stimuli.

Lundqvist D, Svärd J, Michelgård Palmquist Å, Fischer H, Svenningsson P.

Neuropsychology. 2017 Sep;31(6):605-612. doi: 10.1037/neu0000371. Epub 2017 Jun 5.

PMID:
28581310
48.

Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease.

Ran C, Wirdefeldt K, Brodin L, Ramezani M, Westerlund M, Xiang F, Anvret A, Willows T, Sydow O, Johansson A, Galter D, Svenningsson P, Belin AC.

Parkinsons Dis. 2017;2017:4020198. doi: 10.1155/2017/4020198. Epub 2017 May 2.

49.

Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Rame M, Caudal D, Schenker E, Svenningsson P, Spedding M, Jay TM, Godsil BP.

PLoS One. 2017 May 4;12(5):e0177036. doi: 10.1371/journal.pone.0177036. eCollection 2017.

50.

Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study.

Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, Wirdefeldt K.

Neurology. 2017 May 23;88(21):1996-2002. doi: 10.1212/WNL.0000000000003961. Epub 2017 Apr 26.

Supplemental Content

Loading ...
Support Center